Notice of Results

Oxford Biomedica PLC
23 February 2006


                                                                23 FEBRUARY 2006
                                                                            

               OXFORD BIOMEDICA: NOTICE OF FY2005 PRELIMINARY RESULTS


Oxford, UK - 23 February 2006: Oxford BioMedica (LSE: OXB), the leading gene
therapy company, announces that it will be releasing its preliminary results for
the twelve months ended 31 December 2005 on Tuesday, 14 March 2006.


Analyst meeting:

An analyst briefing will be held at 10:00 am on 14 March at the offices of
Buchanan Communications, 45 Moorfields, London EC2.


Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio
web cast of the results presentation.


To connect to the web cast facility, please go to the Company's website: http://
www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the start
of the briefing. This will also be available for replay shortly after the
presentation.


For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive              Tel: [phone]  
                                                               
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications                               Tel: [phone]
                                                                       
Scientific/Trade Press Enquiries:
Katja Stout/ Gemma Bradley
Northbank Communications                                          
                                                      Tel: [phone]


Notes to editors:

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in 2006, and four further
preclinical candidates. The Company is underpinned by over 80 patent families,
which represent one of the broadest patent estates in the field.


The Company has a staff of approximately 70 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet,
Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to a
number of companies including Merck & Co, Biogen Idec and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange